Notice NOT-CA-20-033 from the NIH Guide for Grants and Contracts

Notice NOT-GM-20-024 from the NIH Guide for Grants and Contracts

Notice NOT-AI-20-038 from the NIH Guide for Grants and Contracts

Notice NOT-AG-20-019 from the NIH Guide for Grants and Contracts

Notice NOT-AG-20-018 from the NIH Guide for Grants and Contracts

Notice NOT-OD-20-075 from the NIH Guide for Grants and Contracts

Notice NOT-TR-20-006 from the NIH Guide for Grants and Contracts

Notice NOT-OD-20-074 from the NIH Guide for Grants and Contracts

Notice NOT-DK-20-013 from the NIH Guide for Grants and Contracts

Notice NOT-OD-20-076 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AI-20-003 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to support development of promising universal influenza vaccine candidates that protect against both influenza A and B viruses.

Notice NOT-CA-20-014 from the NIH Guide for Grants and Contracts

Notice NOT-GM-20-017 from the NIH Guide for Grants and Contracts

Notice NOT-DA-20-020 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AG-21-008 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for the next 5-year cycle of the National Longitudinal Study of Adolescent to Adult Health (Add Health) to include a sixth wave of data collection (Wave VI). Add Health is a nationally representative, longitudinal study of individuals primarily born from 1976 through 1982 who were first interviewed as adolescents in grades 7-12 (ages 12-19) in 1994-1995. Add Health respondents are now entering middle age. The goals for Add Health Wave VI are to: Re-interview Add Health cohort members in a combination of web-based and in-person modes, including aggressive non-response follow-up and oversamples of race/ethnic-minority and low-socioeconomic-status individuals. Re-visit cohort members for an in-home health exam that includes venous blood collection. Assay biological specimens for biomarkers of disease. Enrich measures in domains that may elucidate mid- and later-life health and disparities therein (e.g., cumulative stress, discrimination, work-life balance, caregiving). Clean, document, disseminate, archive (including storage of biological specimens for future study), and promote the Wave VI data to the scientific community for aging research.

Funding Opportunity RFA-MD-20-007 from the NIH Guide for Grants and Contracts. NIMHD invites applications from eligible institutions to establish a national coordinating center (CC) for NIMHD-funded Research Centers in Minority Institutions (RCMIs). The primary goals of RCMI Specialized Centers are to: (1) enhance institutional research capacity within the areas of basic biomedical, behavioral, and/or clinical research; (2) enable all levels of investigators to become more successful in obtaining competitive extramural support, especially from NIH, particularly on diseases that disproportionately impact minority and other health disparity populations; (3) foster environments conducive to career enhancement with a special emphasis on development of early career investigators; (4) enhance the quality of all scientific inquiry and promote research on minority health and health disparities; and (5) establish sustainable relationships with community-based organizations that partner with RCMI centers. The RCMI CC will work closely with key personnel at all RCMI sites and with NIMHD staff to promote and facilitate communication and collaboration across RCMI sites nationwide to help them collectively achieve these RCMI program objectives. The RCMI CC will be responsive to requests generated by RCMI site key personnel, NIMHD, NIH, the scientific community, and the general public. Eligible applicant institutions for this FOA are limited to those currently funded by the RCMI program through RFA-MD-17-003, RFA-MD-17-006, or RFA-MD-18-012.

Funding Opportunity PAR-20-118 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to accelerate innovative drug and device therapies translation from discovery to early human studies. Studies responsive to this FOA will develop pharmacologic and neuromodulatory tools for basic and clinical research on mental health disorders, substance use disorders (SUDs) or alcohol addiction; develop and validate tools (pharmacologic or neurostimulation) in support of experimental therapeutic studies of innovative new candidates for mental disorders; and support early-stage human studies to rapidly assess the safety, tolerability, and pharmacodynamics of promising drug candidates/devices and new indications for novel Investigational New Drug (IND)-ready agents or Investigational Device Exemption (IDE)-ready devices for the treatment of mental disorders, SUDs or alcohol addiction.

Funding Opportunity RFA-AG-21-006 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports concerted efforts that take a multipronged, team science strategy and apply high throughput, genome-wide approaches to systematically discover and characterize functional genomic and epigenomic elements; and elucidate and validate their functional roles and mechanisms of action underpinning the heterogeneity, pathogenesis, and progression of Alzheimers disease andrelated dementias (AD/ADRD).

Notice NOT-AR-21-005 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-20-119 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to: accelerate innovative drug and device discovery; develop pharmacologic and neuromodulatory tools for basic and clinical research on mental health, substance use disorders (SUDs) or alcohol use disorder (AUD); develop and validate tools (pharmacologic or neurostimulation) in support of experimental therapeutic studies of innovative new candidates for mental disorders, SUDs or AUD; and support early-stage human studies to rapidly assess the safety, tolerability, and pharmacodynamics of promising drug candidates/devices and new indications for novel Investigational New Drug (IND)-ready agents or Investigational Device Exemption (IDE)-ready devices for the treatment of mental disorders, SUDs or AUD. This FOA encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders, SUDs or AUD, and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged.